The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster presentation MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract presenting preliminary data from the phase 2 combination ...

A downtrend has been apparent in Affimed N.V. (AFMD) lately. While the stock has lost 12% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the s ...

Shares of Affimed N.V. (AFMD) have gained 16.8% over the past four weeks to close the last trading session at $6.66, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $24.20 indicates a potential upside of 263.4%.The mean estimate comprises five short-term price targets with a standard deviation of $27.54. While the lowest estimate of $5 indicates a 24.9% decline from the current ...

Exhibit 99.1 PRESS RELEASE Affimed Reports 2023 Financial Results and Operational Progress • AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR-wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily pretreated patients who were evaluated. Mature progression free survival (PFS) data from the 15 EGFR-wildtype NSCLC patients and i ...

Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ET Company Participants Alexander Fudukidis – Head-Investor Relations Andreas Harstrick – Chief Medical Officer and Interim Acting Chief Executive Officer Michael Wolf – Vice President-Finance Conference Call Participants Srikripa Devarakonda – Truist Daina Graybosch – Leerink Partners Operator Good day, everyone, and welcome to Affimed's Fourth Quarter and Full Year 2023 Earnings and Corporate Update Call. At this time all p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF T ...

MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2023 results and corporate update on March 28, 2024. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in t ...

Affimed N.V. (AFMD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individu ...

Affimed (NASDAQ:AFMD) stock is on the move Friday as investors prepare for the clinical-stage biopharmaceutical company’s shares to undergo a reverse split later today.AFMD stock will go through a one-for-10 reverse stock split after markets close today. That will result in the company’s shares starting to trade on a split-adjusted basis when markets open on Monday.Shareholders approved of this reverse stock split during the company’s on June 21, 2023. It’s also worth mentioning that this split won’t allow ...

I’m about to drop a truth bomb about speculative stocks under $1.Back when I was a freshman in college, the on-campus security officer had this to say: “Tijuana? You don’t wanna.” Subsequently, the crowd erupted in laughter but the officer got his point across. Yes, Tijuana is an exciting and vibrant city, no doubt about it. However, people – especially young underage college students – can get carried away.That’s the reality behind speculative stocks under $1. It’s like Tijuana, where the same restrictions ...